These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 401126)

  • 1. Inhibition of peripheral aromatization in postmenopausal women with breast cancer.
    Barone RM; Judd HL
    Surg Forum; 1978; 29():172-4. PubMed ID: 401126
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo effects of delta 1-testololactone on peripheral aromatization.
    Judd HL; Barone RM; Laufer LR; Gambone JC; Monfort SL; Lasley BL
    Cancer Res; 1982 Aug; 42(8 Suppl):3345s-3348s. PubMed ID: 7083208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-estrogen production rates in postmenopausal women with breast cancer.
    Kirschner MA; Cohen FB; Ryan C
    Cancer Res; 1978 Nov; 38(11 Pt 2):4029-35. PubMed ID: 568029
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using delta 1-testololactone.
    Barone RM; Shamonki IM; Siiteri PK; Judd HL
    J Clin Endocrinol Metab; 1979 Nov; 49(5):672-6. PubMed ID: 489709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen synthesis in human breast tumor and its inhibition by testololactone and bromoandrostenedione.
    Dao TL
    Cancer Res; 1982 Aug; 42(8 Suppl):3338s-3341s. PubMed ID: 7083197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
    Lundgren S; Helle SI; Lonning PE
    Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
    van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
    Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women.
    Miyoshi Y; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2003 Jun; 9(6):2229-33. PubMed ID: 12796390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
    Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
    Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origin of serum estradiol in postmenopausal women.
    Judd HL; Shamonki IM; Frumar AM; Lagasse LD
    Obstet Gynecol; 1982 Jun; 59(6):680-6. PubMed ID: 7078905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between urine and plasma estrogen ratios.
    Longcope C; Pratt JH
    Cancer Res; 1978 Nov; 38(11 Pt 2):4025-8. PubMed ID: 698950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Androstenedione conversion in human peripheral blood lymphocytes].
    Bershteĭn LM; Larionov AA; Kriukova OG
    Biull Eksp Biol Med; 1994 May; 117(5):517-9. PubMed ID: 9296707
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease.
    Reed MJ; Cheng RW; Noel CT; Dudley HA; James VH
    Cancer Res; 1983 Aug; 43(8):3940-3. PubMed ID: 6683128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proceedings: Radioimmunoassay of blood estrone and estradiol in patients with mammary gland diseases (with special reference to breast cancer].
    Suemasu K; Okada T; Izuo M; Fujimori M; Takikawa H
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb; 50(2):303. PubMed ID: 4476416
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
    Dowsett M; Cunningham DC; Stein RC; Evans S; Dehennin L; Hedley A; Coombes RC
    Cancer Res; 1989 Mar; 49(5):1306-12. PubMed ID: 2917360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
    Wilking N; Carlström K; Sköldefors H; Theve NO; Wallgren A
    Acta Chir Scand; 1982; 148(4):345-9. PubMed ID: 6215811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral production of oestrogens in postmenopausal women [proceedings].
    Hutton JD; Murray MA; Goodall A; Baxendale P; Jacobs HS; James VH
    J Endocrinol; 1978 May; 77(2):1P-2P. PubMed ID: 660030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.